TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01614184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein
Description: Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
Study: NCT02246348

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Recording Doppler ultrasound noninvasively from the right chest wall
Study: NCT03009409

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
Study: NCT02395666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
Study: NCT01824342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection
Study: NCT01471951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single embryo transfer in women at risk of multiple pregnancies
Description: Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
Study: NCT00198536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecabet 2.83%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecabet 3.70%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT01710605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells counting at baseline
Description: 20 ml blood sample collected before randomization

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Circulating tumor cells counting at baseline
Description: 20 ml blood sample collected before randomization
Study: NCT02684396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-648 Placebo
Description: TAK-648 placebo-matching solution
Study: NCT01291641

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMG-CoA Reductase Inhibitor
Description: During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probucol
Description: In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route
Study: NCT01089530

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Lifestyle intensive group
Description: hipocaloric diet smoking cessation physical exercise
Study: NCT00605176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod cream
Description: cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod cream
Description: cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
Study: NCT01514513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licefreee Spray
Description: Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% permethrin creme rinse
Description: Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
Study: NCT01704534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
Study: NCT02123524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05271227

Intervention type: OTHER
Intervention: Transthoracic echocardiography and Carotid artery doppler (PHILIPS HD11 XE ultrasound device) before and after PLR test.
Description: VTI-LVOT was measured by echo by placing the pulsed wave Doppler sample gate in the LVOT diameter in apical-5-chamber window. VTI-LVOT was obtained by manually tracing the Doppler velocity spectrum. LVOT velocity time integral was recorded before and after PLR test within 2 minutes. Carotid blood flow was measured by using two-dimensional image, the optimal image of the long-axis view was obtained at the common carotid artery. The sample volume was placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination,The angle correction cursor was placed parallel to the direction of blood flow. A PLR will be performed in 2 sequential steps, first step patient is seated in the semi recumbent position (45°) then using an automatic bed elevation technique, the lower limbs will be then raised to a 45° angle while the patient's trunk will be lowered in supine position. Thus, the angle between the trunk and the lower limbs will remain unchanged (135°).
Study: NCT03147924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improvisation Group
Description: The aim of this pilot study is to investigate the effects of improvisational comedy in a group of help-seeking youth at risk of developing a range of mental health disorders, including social anxiety.
Study: NCT02505724

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional training
Description: After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer-coaching
Description: Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
Study: NCT02418754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2176-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2176-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2176-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)
Study: NCT03724682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carry Life UF device
Description: Treatment with the Carry Life UF device compared to standard PD therapy
Study: NCT01097551

Intervention type: DRUG
Intervention: Trinitrin
Description: Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose

Intervention type: DRUG
Intervention: Trinitrin
Description: Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose

Intervention type: DRUG
Intervention: Neosynephrine 10% collyrium
Description: Neosynephrine 10% collyrium: 2 drops

Intervention type: DRUG
Intervention: Neosynephrine 10% collyrium
Description: Neosynephrine 10% collyrium: 2 drops

Intervention type: DRUG
Intervention: Iontophoresis with acetylcholine delivery
Description: Iontophoresis with acetylcholine delivery
Study: NCT04418154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin bound paclitaxel
Description: Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
Study: NCT02904096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse injectable implant and 2% lidocaine HCL
Description: Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse injectable implant and 2% lidocaine HCL
Description: Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
Study: NCT01978301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
Study: NCT03888287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watch Rx system
Description: The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watch Rx system
Description: The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parkinson's Disease Inpatient Clinical Knowledge and Management Program
Description: Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parkinson's Disease Inpatient Clinical Knowledge and Management Program
Description: Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parkinson's Disease Inpatient Clinical Knowledge and Management Program
Description: Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
Study: NCT01942460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Study: NCT03358173

Intervention type: PROCEDURE
Intervention: Conservative Treatment
Description: Conservative Treatment

Intervention type: PROCEDURE
Intervention: Operative Plate Fixation
Description: Operative Plate Fixation
Study: NCT03184025

Intervention type: OTHER
Group type: OTHER
Intervention: dentin adhesive
Description: HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
Study: NCT02825563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: in the high fat diet
Study: NCT02941029

Intervention type: OTHER
Intervention: Plasma Blood collection
Description: Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
Study: NCT01276600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir
Description: 200mg of emtricitabine 300mg of tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir
Description: 200mg of emtricitabine 300mg of tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir
Description: 200mg of emtricitabine 300mg of tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir
Description: 200mg of emtricitabine 300mg of tenofovir
Study: NCT02439983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary Nutritional Supplement
Description: 2 capsules taken by mouth with morning and evening meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules taken by mouth with morning and evening meals.
Study: NCT02661685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous IKDC-like cells
Description: Subject received autologous IKDC-like cells every 14 days
Study: NCT01783288

Intervention type: OTHER
Group type: OTHER
Intervention: Autonomic Function Testing
Description: heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.~Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed.

Intervention type: OTHER
Group type: OTHER
Intervention: Posture Study
Description: Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured \& collected in the supine (lying) and upright position for each participant.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measurement of Total Blood Volume
Description: Total blood volume is measured by using iodinated I-131 tagged human serum albumin.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Capacity Test
Description: Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
Study: NCT02486302

Intervention type: DRUG
Intervention: Etanercept
Description: Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
Study: NCT02090075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apixaban
Description: 5 po or 2.5 po bid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: warfarin
Study: NCT03947996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercise
Description: Stretching (30 minutes, 5 days per week, 8 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Walking (30 minutes, 5 days per week, 8 weeks)
Study: NCT04393285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 150mg orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg orally once a day
Study: NCT04343820

Intervention type: PROCEDURE
Intervention: Breast reconstruction
Description: Breast reconstruction by prepectoral positioned implant after lipo-preparation of the wall.
Study: NCT02330965

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood draws (65 mLs \[\~4 tablespoons\] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
Study: NCT01414816

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: EOD, dosage frequency and duration will be decide by physicians.
Study: NCT00921856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracoronary acetylcholine provocation test
Description: Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
Study: NCT03251651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
Study: NCT01234194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rising remifentanil concentrations
Description: remifentanil effect-compartment concentrations 0,1,2,3 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: falling remifentanil concentrations
Description: remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
Study: NCT03770624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007 tablet
Description: QL-007 will be administered orally daily over the 28 days under fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007 tablet
Description: QL-007 will be administered orally daily over the 28 days under fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007 tablet
Description: QL-007 will be administered orally daily over the 28 days under fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007 tablet
Description: QL-007 will be administered orally daily over the 28 days under fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007 tablet
Description: QL-007 will be administered orally daily over the 28 days under fasted state.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: TDF will be administered orally daily over the 28 days e.
Study: NCT02704481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200mg oral mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 800mcg buccal misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 800mcg buccal misoprostol
Study: NCT03641989

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plaque disclosing toothpaste
Description: Plaque identifying toothpaste with a FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-plaque disclosing toothpaste
Description: Toothpaste that does not contain the FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
Study: NCT02702908

Intervention type: OTHER
Description: Historical Reference group.
Study: NCT01097551

Intervention type: DRUG
Intervention: Iontophoresis with acetylcholine delivery
Description: Iontophoresis with acetylcholine delivery

Intervention type: DEVICE
Intervention: Dynamic Vessel Analyzer
Description: Dynamic Vessel Analyzer

Intervention type: DEVICE
Intervention: Dynamic Vessel Analyzer
Description: Dynamic Vessel Analyzer
Study: NCT01047033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: 30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microcredit
Description: Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microcredit
Description: Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
Study: NCT03365791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
Study: NCT03558035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction CT+ CRT group
Description: Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent CRT group
Description: cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy